El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Sartorius Stedim Biotech.
Cerrado
SectorFinanzas
206.1 -0.29
Resumen
Variación precio
24h
Mínimo
205.7
Máximo
206.1
Ingresos | -28M 64M |
|---|---|
Ventas | -39M 706M |
P/B Media del Sector | 76.029 29.597 |
BPA | 0.94 |
Margen de beneficios | 9.097 |
Empleados | 10,134 |
EBITDA | 16M 218M |
Recomendaciones | Compra Fuerte |
|---|---|
Estimación a 12 Meses | +14.13% upside |
Capitalización Mercado | -49M 20B |
|---|---|
Apertura anterior | 206.39 |
Cierre anterior | 206.1 |
Noticias sobre sentimiento de mercado
By Acuity
21%
79%
39 / 526 Clasificación en Finance
Puntuación técnica
By Trading Central
Confianza
Bullish Evidence
Sartorius Stedim Biotech. Gráfico
Resultados pasados no son un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
Sartorius Stedim Biotech. previsión
Precio Objetivo
By TipRanks
14.13% repunte
Estimación a 12 Meses
Media 235 EUR 14.13%
Máximo 260 EUR
Mínimo 210 EUR
De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Sartorius Stedim Biotech. Dist en los últimos 3 meses.
Sentimiento
By Acuity
39 / 526 Clasificación en Finanzas
Noticias sobre sentimiento de mercado
Coyuntura alcista notoria
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de Sartorius Stedim Biotech.
Sartorius Stedim Biotech S.A. engages in the production and sale of instruments and consumables for the biopharmaceutical industry worldwide. The company offers various products, such as cell lines; cell culture media; bioreactors; advanced therapies; and a range of products for separation, purification, and concentration processes, as well as products and systems for storage and transportation of intermediate and finished biological products. It also provides cell cultivation, fermentation, separation, purification, and fluid management services; biolayer interferometry instruments; microbiology enumeration, sterility testing, and air monitoring instruments; pipette products; sensors and analyzers; biomolecule analysis tools; flow cytometry; batch and intensified chromatography systems; lab data and fleet management software; live cell imaging and analysis; surface plasmon resonance solutions; and weighing products. In addition, the company offers data analytics software for modeling and optimizing processes of biopharmaceutical development and production; process automation platform and software; and develops and produces transfection, as well as other DNA/RNA delivery reagents and plasmid DNA. It serves manufacturers of medications, vaccines, foods, and chemicals, as well as research and development laboratories. The company was incorporated in 1978 and is headquartered in Aubagne, France. As of December 31, 2023, Sartorius Stedim Biotech S.A. operates as a subsidiary of Sartorius AG.
Live chat